Oral anticancer medications are increasingly important but costly treatment options for patients with cancer. By early 2017, 43 states and Washington, DC, had passed laws to ensure patients with private insurance enrolled in fully insured health plans pay no more for anticancer medications administered by mouth than anticancer medications administered by infusion. Federal legislation regarding this issue is currently pending. Despite their rapid acceptance, the changes associated with state adoption of oral chemotherapy parity laws have not been described.
O rally administered anticancer medications are an increasingly important part of cancer treatment. By mid-2015, there were more than 50 orally administered anticancer medications approved by the US Food and Drug Administration, with more medications anticipated in coming years. These medications are expensive, with list prices often exceeding $100 000 per year. 1, 2 Proponents of legislation aimed at limiting out-of-pocket expenditures for patients suggest that anticancer medications obtained under a patient's pharmacy benefit can require higher enrollee cost sharing than infused medications covered under the medical benefit, 3 potentially affecting patient access to outpatient prescriptions. [4] [5] [6] [7] In response, since 2008, 43 states and Washington, DC, have passed oral chemotherapy parity laws to ensure cost-sharing equality for oral and infused anticancer medications. 8 These laws are intended to ensure that cost sharing (eg, copayments, coinsurance, or benefit limits) for patients is equivalent for anticancer drugs obtained with either medical (infused) or pharmacy (oral) benefits. Despite their rapid acceptance, the association of the state oral chemotherapy parity laws with oral anticancer medication use and patient and health care spending is unknown.
Methods
We used 2008-2012 national administrative health plan claims from the Health Care Cost Institute for privately insured members of Aetna, Humana, and UnitedHealthcare to estimate the association of oral chemotherapy parity laws with the use of orally administered anticancer drugs and their out-of-pocket spending. Original analysis of data was completed in 2015; revisions were updated in 2017. We studied 72 500 patients aged 18 through 64 years who had prescription drug coverage; lived in 16 states implementing parity laws between July 1, 2008, through July 15, 2012; were treated with infused or orally administered anticancer medication; and were assigned diagnosis codes for a cancer for which orally administered drugs were available. We excluded 6104 individuals without 3 months of continuous health plan enrollment before the observation month (for comorbidity measurement) and 2616 individuals missing insurance plan funding status. In total, 63 780 individuals with 375 387 person-months of anticancer medication use were included. This study received an exemption from the University of North Carolina at Chapel Hill Institutional Review Board. We identified infused anticancer therapy from outpatient and physician service claims and orally administered anticancer medications from pharmacy claims. As in previous work by others, 9,10 we included targeted orally administered anticancer medications and capecitabine (which has an infused equivalent) but excluded breast cancer endocrine therapies (eMethods 1 and eTable 1 in the Supplement). We measured oral anticancer therapy use as a proportion of all anticancer therapy provided in each person-month. We summarized out-of-pocket spending per prescription fill on oral anticancer medications, including copayment, coinsurance, and deductibles, adjusting to reflect spending on a median monthly dosage. We also summarized 6-month total health care spending beginning with the patient's first observed anticancer therapy.
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Statistical Analysis
We used a propensity score-weighted, difference-indifferences approach to estimate the net association of parity with the use of orally administered anticancer drugs and outof-pocket spending among individuals in fully insured plans, controlling for changes over time among individuals in selffunded plans (not subject to parity laws via the Employee Retirement Income Security Act [ERISA]) in those states.
12 A 2-sided t test was used, and P < .05 was considered statistically significant. Our 3 models with binary outcomes included the probability of (1) using oral anticancer medications, (2) paying $0 per month for orally administered anticancer medications, and (3) paying more than $100 per month for orally administered anticancer medications. We used generalized estimating equations with logarithmic links and binomial distributions to account for repeated observations. 13 As a result of parity laws, we observed nonlinear changes in out-of-pocket spending and used quantile regression to estimate changes at the 25th, 50th, 75th, 90th, and 95th percentiles of monthly out-of-pocket spending. 14,15 Finally, for 6-month total health care spending, we used generalized estimating equations with logarithmic links and gamma distributions and retransformed model estimates to 2012 US dollars. Data analyses were performed with PROC QUANTREG and PROC GENMOD in SAS, version 9.4 (SAS Institute Inc). For further model descriptions and sensitivity analyses, see eMethods 2 in the Supplement.
Results
Of 63 780 individuals aged 18 to 64 years and using anticancer medications in states that passed parity laws during the study period, 51.4% participated in fully insured plans and 48.6% in self-funded plans (57.2% were women; 76.8% were aged 45-65 years). After propensity score weighting, patients
Key Points
Question How have state parity laws regarding coverage for orally administered chemotherapy drugs changed their use, out-of-pocket spending, and total health plan expenses?
Findings In this analysis of health claims data from 3 nationwide insurers involving 63 780 adults, state parity laws appeared to reduce monthly spending on prescription fills at the lower end of the out-of-pocket spending distribution but appeared to increase spending for prescription fills with the highest out-of-pocket spending. Parity laws were not associated with changes in 6-month total health care spending.
Meaning Although oral chemotherapy parity laws have been widely adopted by states, these laws have not consistently reduced out-of-pocket spending for orally administered anticancer medications.
were well balanced on measured characteristics (eTable 2 in the Supplement).
Oral anticancer medication use as a proportion of all anticancer medication use increased from approximately 18% to 22%, with no significant differences attributed to parity laws (adjusted difference-in-differences risk ratio [aDDRR], 1.04; 95% CI, 0.96-1.13; P = .34).
In both fully insured and self-funded health plans, monthly out-of-pocket spending was $50 or less for most prescription fills of orally administered and infused anticancer medications both before and after parity laws (eFigures 1 and 2 in the Supplement). After parity laws, the probability of paying $0 per month for orally administered anticancer medications more than doubled in fully insured plans (from 15.0% to 53.0%) compared with self-funded plans (from 12.3% to 18.0%) (aDDRR, 2.36; 95% CI, 2.00-2.79; P < .001). However, there was an increase in the proportion of prescription fills with out-ofpocket spending of more than $100 per month in fully insured plans (from 8.4% to 11.1%) vs self-funded plans (from 12.0% to 11.7%) during the same period (aDDRR, 1.36; 95% CI, 1.11-1.68; P = .004). Among infused treatments, there was no difference in the probability of paying $0 per month (aDDRR, 0.99; 95% CI, 0.89-1.10; P > .05) or the probability of paying more than $100 per month (aDDRR, 1.05; 95% CI, 0.79-1.39;
When considering the distribution of spending, the adoption of state parity laws was associated with modest but statistically significant decreases in estimated monthly out-ofpocket spending on orally administered anticancer medications by $19.44 at the 25th percentile, $32.13 at the 50th, and $10.83 at the 75th (all P < .001, controlling for changes in plans not subject to parity during the same period). However, spending increased by $37.19 at the 90th percentile and $143.25 at the 95th (all P < .001; Figure 1 and eTable 3). In a sensitivity analysis that excluded deductibles, results were consistent, but outof-pocket spending increases of $24.32 (90th percentile) and $49.43 (95th percentile) were somewhat lower and not statistically significant for the 95th percentile.
Before parity, total health care spending for 6-month treatment episodes of all anticancer medication users were a mean of $87 328 (95% CI, $85 481-$89 214) for patients in fully insured plans and $84 103 (95% CI, $82 524-$85 712) for patients in self-funded plans (Figure 2 ). There were no statistically significant changes in spending by parity status (for all anticancer medication users, P = .09; for oral anticancer medication users, P = .40).
Discussion
Although oral chemotherapy parity laws have been widely adopted by states, these laws have not consistently reduced out-of-pocket spending for orally administered anticancer medications. Specifically, parity laws reduced monthly outof-pocket spending on prescription fills at the lower end of the spending distribution but increased spending for prescription fills at the highest end of the spending distribution. Medication fills with $0 per month cost sharing more than doubled, and costs simultaneously increased for medication fills with at least $100 per month in cost sharing after adoption of parity laws.
Our findings illuminate several important issues for privately insured patients. First, plans typically required relatively modest cost sharing before and after parity laws (<$50/ mo). However, approximately 5% of prescription fills had outof-pocket spending of $500 or more in fully insured plans after parity laws, suggesting that parity law requirements alone may Propensity score-weighted, generalized estimating equations with logarithmic links and gamma distributions were used to estimate 6-month spending on health care services. Models were estimated using PROC GENMOD in SAS, version 9.4 (SAS Institute Inc). There were no significant differences in total health care spending as a result of parity laws adoption for all anticancer medication users (adjusted difference-in-differences risk ratio [aDDRR], 0.96; 95% CI, 0.90-1.02; P = .09) or for orally administered anticancer medication users (aDDRR, 1.06; 95% CI, 0.93-1.20; P = .40). not address high out-of-pocket spending for some patients. Second, estimated out-of-pocket spending did not change for patients in self-funded plans, which are exempt from state mandates. Federal legislation would be required to extend parity laws to individuals in self-funded plans. Finally, opposition to state efforts have centered on concerns that improved coverage for orally administered chemotherapy would increase overall health care spending, but we found no evidence of increases from our 6-month health care spending results.
Spending Changes for Oral Anticancer Therapy After State Parity Laws
Limitations
This study has some important limitations. First, we studied 16 states that passed parity laws from 2008 to 2012; thus, our findings may not represent all states with parity laws from more recent time periods. However, parity laws passed more recently are nearly identical to those in the 16 states studied. 8 Second, we could not observe drug manufacturer coupon use or patients who do not fill their prescriptions because of very high cost sharing for their anticancer medication. Third, we studied patients in 3 health plans; thus results may not generalize to other insurers. However, Aetna, Humana, and UnitedHealthcare are among the largest private insurers in the United States. Finally, all orally administered anticancer medications were branded products, and out-of-pocket spending requirements may differ for generic or biosimilar medications.
Conclusions
Our findings suggest that, while state oral chemotherapy parity laws modestly improved financial protection for many patients without increasing total health care spending, these laws alone may be insufficient to ensure that patients are protected from high out-of-pocket costs. In this model, we include main effects for each of our key independent variables (Parity and Post) as well an interaction between the two. 1 represents the impact of being in a fully-insured plan that is subject to parity; 2 represents the impact of time, 3
represents the effect of parity on post-parity outcomes (Y).
A difference-in-difference design is well-suited to study the effects of a policy change by assessing outcomes of interest before and after a policy change while also incorporating a comparison group that is also experiencing time trends but is not exposed to the policy change (See Dimick et al, 2014 JAMA "Methods for Evaluating
Changes in Health Care Policy: The Difference-in-Differences Approach" for further discussion). Thus, two groups are followed over time and outcomes are compared by group and time. In the current study, we compare health plans that are subject to parity (fully insured plans, the intervention group) with plans that are not subject to parity (selffunded plans, the control group), examining outcomes before and after parity was implemented during each period. This allows for clear comparisons of changes in the intervention group (fully-insured plans) while controlling for changes occurring over time in the outcome among the control group (self-funded plans). This method allows for identification and control of temporal variation in the outcome not due to treatment exposure (exposure to parity).
In addition to applying the DD framework for estimating the impact of parity, we further used propensity score weighting to better balance baseline characteristics of patients in self funded and fully insured plans. We estimated a propensity score by modeling the probability of being in a fully-insured versus self-funded plan at the time of the patient's index claim. The propensity score model included state, age, sex, cancer type, health plan type (HMO, POS, PPO, other), comorbidity (measured via the Klabunde comorbidity score and number of medications used in prior 3 months), zip code-level socioeconomic variables from the 2010 American Community Survey, and rurality of residence. We applied the propensity score to all analyses using inverse probability of treatment weights.
Sensitivity Analyses
In sensitivity analyses we estimated changes in mean out-of-pocket spending, rather than the distribution of spending. For all spending models we used a modified Park test to determine the best fitting distribution but also tested alternative definitions of the distributional family and link functions to ensure our findings were robust. Next, for total health care spending, we restricted our sample to those with continuous health plan enrollment during the six-month treatment episode (81.2% of the sample). Finally, although our primary modeling strategy took advantage of within-state controls, we also estimated models matching five states that had not passed parity over the study period to those that had in a difference-in-difference-in-differences model. Results of all sensitivity analyses were consistent with the primary analysis and not presented. , 2008-2012 . After parity, the probability of paying $0 for orally-administered anticancer medications more than doubled in fully-insured plans compared with self-funded plans (aDD RR:2.36, 95%CI:2.00-2.79). There was an increase in the proportion of fills with out-of-pocket spending of >$100 in fullyinsured plans relative to self-funded plans (aDD RR: 1.36, 95%CI: 1.11-1.68). ). No differences were seen between fully-insured and self-funded plans when considering infused anticancer therapy out-of-pocket costs (all p > 0.05). 
